




Supplementary Figure 1. Intra-batch reproducibility of biomarker measurement in whole plasma. A) Reproducibility of six replicate measurements in IPM; B) Reproducibility of six replicates in IPM/ALB ratio.

Supplementary Table 1. Summary of diagnostic and demographic information for the clinic plasma cohorts

Total samples		UPMC (n=100)			Mayo Clinic (n=30)		
PDAC		n=50	Age	Gender	n=10	Age	Gender
Stage	Ia	3	Avg. Age=67 yrs (48 yrs - 89 yrs)	Female 46%, Male 54%	1	Avg. Age=72 yrs (62 yrs-81 yrs)	Female 20%, Male 80%
	Ib	1			9		
	IIa	11					
	IIb	35					
	III	0					
	VI	0					
Control		n=50	Age	Gender	n=20	Age	Gender
Normal pancreas		18	Avg. Age=64 yrs (37 yrs - 84 yrs)	Female 56%, Male: 44%		Avg. Age=72 yrs (63 yrs-76 yrs)	Female 20%, Male 80%
Healthy		3			10		
Chronic pancreatitis		22			10		
Chronic pancreatitis / IPMN		3					
IPMN		1					
Other benign diseases		3					

Supplementary Table 2. Endogenous peptides used for the calibration of retention time in building a spectral library

FVTQAEGAK	EGYYGYTGAFR
SYSCQVTHEGSTVEK	QSGLYFIKPLK
AHYGGFTVQNEANK	VHQYFNVELIQPGAVK
THLAPYSDEL R	GAYPLSIEPIGVR
<u>C</u> DEWSVNSVGK	QEPSQGTTTFAVTSILR
VG YVSGWGR	QFSFPLSSEPFQGSYK
FSAI <u>C</u> QGDGTWSPR	<u>C</u> EGPIPDVTFELLR
EWFWDLATGTMK	

Supplementary Table 3. Performance of the five individual biomarkers and CA19-9 in distinguishing PDAC from non-PDAC samples using ROC analysis

Biomarker	AUC	AUC (95% CI)
Apolipoprotein A-IV (APOA4)	0.68	0.58-0.79
Complement component 3 (C3)	0.70	0.60-0.80
Leucine-rich alpha-2-glycoprotein 1 (LRG1)	0.74	0.64-0.84
Alpha-1-acid glycoprotein (ORM1)	0.75	0.55-0.85
Plasma protease C1 inhibitor (SERPING1)	0.72	0.63-0.82
CA19-9	0.67	0.56-0.78

Supplementary Table 4. Inter-batch reproducibility: the repeatability coefficient of variation (CVr) and the time-dependent coefficient of variation (CVt) for all five biomarkers.

	CVt	CVr
APOA4	9%	4%
C3	7%	3%
LRG1	11%	6%
ORM1	12%	8%
SERPING1	8%	4%